section name header

Pronunciation ⬇

ter-AY-zoe-sin

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: peripherally acting antiadrenergics

Indications ⬆ ⬇

BEERS REMS

Action ⬆ ⬇

  • Dilates both arteries and veins by blocking postsynaptic alpha1-adrenergic receptors.
  • Decreases contractions in smooth muscle of the prostatic capsule.
Therapeutic effects:
  • Lowering of BP.
  • Decreased symptoms of BPH (urinary urgency, hesitancy, nocturia).

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: 50% metabolized by the liver. 10% excreted unchanged by the kidneys. 20% excreted unchanged in feces. 40% eliminated in bile.

Half-Life: 12 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSET‡PEAK‡DURATION‡
PO-hypertension15 min6–8 wk24 hr
PO-BPH2–6 wkunknownunknown



‡After single dose.

‡After multiple oral dosing.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: first-dose orthostatic hypotension, arrhythmias, chest pain, palpitations, peripheral edema, tachycardia

Derm: pruritus

EENT: nasal congestion, blurred vision, conjunctivitis, intraoperative floppy iris syndrome, sinusitis

GI: nausea, abdominal pain, diarrhea, dry mouth, vomiting

GU: erectile dysfunction, urinary frequency

Metab: weight gain

MS: arthralgia, back pain, extremity pain

Neuro: dizziness, headache, weakness, drowsiness, nervousness, paresthesia

Resp: dyspnea

Misc: fever

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Hypertension

Benign Prostatic Hyperplasia

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Hytrin

Code ⬆

NDC Code